XML 35 R22.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENT INFORMATION (Tables)
3 Months Ended
Dec. 31, 2023
SEGMENT INFORMATION  
Schedule of information regarding operations by segment

Information regarding operations by segment for the three-month period ended December 31, 2023 is as follows:

Therapeutic DNA

MDx Testing

DNA Tagging and

    

    

Production

    

Services and Kits

    

Security Products

    

Consolidated

Revenues

 

  

 

  

 

  

 

  

Product revenues

$

$

$

307,317

$

307,317

Service revenues

 

77,535

 

 

169,612

 

247,147

Clinical laboratory service revenues

 

 

342,740

 

 

342,740

Less intersegment revenues

 

 

(6,040)

 

 

(6,040)

Total revenues

$

77,535

$

336,700

$

476,929

$

891,164

Gross profit

$

77,535

$

(62,958)

$

216,520

$

231,097

(Loss) from segment operations (a)

$

(1,259,046)

$

(496,512)

$

(784,303)

$

(2,539,861)

Information regarding operations by segment for the three-month period ended December 31, 2022 is as follows:

Therapeutic DNA

MDx Testing

DNA Tagging and

    

    

Production

    

Services

    

Security Products

    

Consolidated

Revenues:

 

  

 

  

 

  

 

  

Product revenues

$

127,506

$

$

388,890

$

516,396

Service revenues

 

121,743

 

 

110,318

 

232,061

Clinical laboratory service revenues

 

 

4,565,815

 

 

4,565,815

Less intersegment revenues

 

 

(51,520)

 

 

(51,520)

Total revenues

$

249,249

$

4,514,295

$

499,208

$

5,262,752

Gross profit

$

170,924

$

1,933,219

$

273,540

$

2,377,683

(Loss) income from segment operations (a)

$

(852,253)

$

1,109,884

$

(474,715)

$

(217,084)

Schedule of reconciliation of segment loss from operations to corporate loss

December 31, 

    

2023

    

2022

Loss from operations of reportable segments

$

(2,539,861)

$

(217,084)

General corporate expenses (b)

 

(1,249,205)

 

(1,001,894)

Interest income

 

33,323

 

3,686

Unrealized gain (loss) on change in fair value of warrants classified as a liability

 

2,639,000

 

(2,637,800)

Other (expense) income, net

(13,538)

8,846

Consolidated loss before provision for income taxes

$

(1,130,281)

$

(3,844,246)

(a)

Segment operating loss consists of net sales, less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses.

(b)

General corporate expenses consist of Selling, general and administrative expenses that are not specifically identifiable to a segment.